Alembic Pharmaceuticals Ltd.
Snapshot View

946.65 +2.25 ▲0.2%

23 July 2021, 04:00:00 P.M.
Volume: 18,091

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.alembicpharmaceuticals.com
Financial Indicators
Market Cap 18,607.65 Cr.
Earnings per share (EPS) 59.94 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 15.79 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 260.86 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.63 Calculated using Price: 946.65
Dividend Yield 1.48 Period Ending 2021-03
No. of Shares Subscribed 19.66 Cr. 196,563,124 Shares
FaceValue 2
Company Profile

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.

Business area of the company

The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.

Awards and recognition

  • Forbes India Awards Mr Pranav Amin and Mr. Shaunak Amin as ‘NextGen Entrepreneurs of the Year’
  • 1st Runner up Position in Job Safety Analysis(JSA) - at CII Industrial Safety Summit 2016
  • The company’s Commitment towards Risk Management honoured at Gujarat Seminar and Conclave on Risk Management.
  • The company’s MDs honoured with 'Transformational Leader Award'
  • The company won 'HR event of the Year' and 'Outstanding contribution to the cause of Education' at the 'Gujarat Best Employer Brand Awards 2017'
  • The company won 'HR event of the Year' at the 'Gujarat Best Employer Brand Awards 2017'

Milestones

  • 1907: Started manufacturing tinctures and alcohol at Vadodara.
  • 1940: Started manufacturing cough syrup, vitamins, tonics and sulphur drugs.
  • 1961: Lal bahadur Shastri inaugurates the Penicillin plant.
  • 1967: Bulk manufacturing of Vitamin B12.
  • 1971: Erythromycin manufactured for the first time in India.
  • 1972: Althrocin a brand of Erythromycin launched.
  • 1997: Althrocin becomes top selling brand in India.
  • 1999: Alembic starts production of synthetic organic API.
  • 2000: Gets ISO 14000 certification for its facilities at Vadodara.
  • 2001: Starts manufacturing of Cephalosporin C.
  • 2007: Acquisition of non - oncology business of Dabur Pharma Ltd.
  • 2009: Addressed chronic therapies through multiple marketing divisions.
  • 2010: ANDA’s total filed 38. DMF total filed to 53 and get approval for 15.
  • 2011: Pharmaceutical Business demerged from Alembic - APL Listed.
  • 2012: Launched Dermatology division in domestic market with 8 products.
  • 2013: Launched first NDA with a partner. Commenced filing in EU, Australia and Brazil.
  • 2014: Formed a JV in Algeria- Alembic MAMI SPA to explore African market.
  • 2015: Launched Aripiprazole on Day-1. Established the U. S front-end, transition to own marketing in the U.S.
  • 2016: Formed JV 60:40 with Orbicular - “Aleor Dermaceuitical Limited” for developing Dermatology Products for international markets.
  • 2017: Shri. Vijay Rupani - Hon’ble Chief Minister of Gujarat, inaugurates the manufacturing facility for Oncology medicines (oral solids and liquid injectable vials).
  • 2017: Acquired Orit Laboratories LLC, USA.
  • 2018: FDA approved Aleor’s dermatology facility.
  • 2018: Highest ever investment commitment across four new manufacturing facilities.
  • 2019: FDA approves Oncology oral solid facility.
  • 2019: Formed a JV, to enter China.
  • 2020: US front-end achieved milestone of $ 250 Mn Sales in 2019-20.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.24%
1 Week
-2.33%
1 Month
-3.51%
3 Month
-5.15%
6 Month
+0.64%
1 Year
-1.55%
2 Year
+78.66%
5 Year
+61.10%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 36.81 39.97 36.24 58.03 23.25 20.42 24.00 26.97 26.71
Return on Capital Employed (%) 32.05 43.54 37.54 65.87 28.87 22.15 22.66 23.30 26.13
Return on Assets (%) 14.79 18.79 18.76 33.76 14.97 12.25 13.15 14.64 17.56

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 503 676 885 1,597 1,902 2,220 2,719 3,219 5,128
Non Curr. Liab. 103 94 72 84 94 576 570 1,047 361
Curr. Liab. 529 603 684 944 814 1,267 1,664 1,752 1,281
Minority Int. 0 0 -1 -29 -61
Equity & Liab. 1,135 1,372 1,641 2,626 2,811 4,064 4,952 5,989 6,709
Non Curr. Assets 416 516 750 917 1,317 2,116 2,820 3,526 4,131
Curr. Assets 719 857 891 1,708 1,494 1,948 2,132 2,463 2,578
Misc. Exp. not W/O
Total Assets 1,135 1,372 1,641 2,626 2,811 4,064 4,952 5,989 6,709

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 1,520 1,863 2,056 3,166 3,135 3,131 3,935 4,606 5,393
Other Income 17 4 12 9 3 35 27 14 87
Total Income 1,537 1,868 2,068 3,175 3,137 3,166 3,962 4,620 5,481
Total Expenditure -1,272 -1,506 -1,661 -2,161 -2,520 -2,516 -3,079 -3,392 -3,913
PBIDT 265 362 407 1,014 617 650 883 1,228 1,568
Interest -24 -10 -4 -5 -5 -3 -18 -27 -16
Depreciation -35 -40 -44 -72 -83 -105 -115 -157 -183
Taxation -41 -75 -76 -216 -122 -120 -157 -199 -253
Exceptional Items -44
PAT 165 236 283 720 407 421 593 801 1,115

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 265 240 172 948 329 312 812 449 1,463
Cash Fr. Inv. -67 -81 -256 -307 -486 -884 -756 -732 -839
Cash Fr. Finan. -229 -151 87 -224 -129 503 59 155 -597
Net Change -31 8 3 417 -286 -69 115 -128 27
Cash & Cash Eqvt 16 24 27 439 153 84 199 72 98

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 72.97 72.97 72.97 72.97 72.97 69.77 69.78 69.48 69.48
Public 27.03 27.03 27.03 27.03 27.03 30.23 30.22 30.52 30.52
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 20 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose herewith a copy of advertisement related to notice for claiming shares from Companys Unclaimed Suspense Account published by the Company in English language newspaper on 20th July 2021 in Business Standard.

We request you to kindly take the same on record.
Thu, 15 Jul 2021
Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 30Th June 2021
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2021 inter alia to consider and approve With reference to the captioned matter the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Monday 26th July 2021 inter-alia to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June 2021.

Pursuant to the Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives the trading window for dealing in securities of the Company which was closed from 1st July 2021 will re-open 48 hours after the declaration of the financial results.

We request you to kindly take the same on record.
Thu, 15 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate as per the attached letter.

We enclose herewith an e-mail intimation received from Link Intime India Private Limited Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company.

We request you to kindly take the same on record.

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Both SRS And ARS Below Zero Both SRS And ARS Below Zero
Closing Near 200 EMA Closing Near 200 EMA
+DI Crossing -DI From Below +DI Crossing -DI From Below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%